CORDIS

EU research results

CORDIS

Implications of Medical Low Dose Radiation Exposure

Fact Sheet

Reporting

Results

Objective

MEDIRAD aims to enhance the scientific bases and clinical practice of radiation protection (RP) in the medical field and thereby addresses the need to understand and evaluate the health effects of low dose ionising radiation exposure from diagnostic and therapeutic imaging and from off-target effects in radiotherapy (RT).
MEDIRAD will pursue 3 major operational objectives: First, it will improve organ dose estimation and registration to inform clinical practice, optimise doses, set recommendations and provide adequate dosimetry for clinical-epidemiological studies of effects of medical radiation. Second, it aims to evaluate and understand the effects of medical exposures, focusing on the two major endpoints of public health relevance: cardiovascular effects of low to moderate doses of radiation from RT in breast cancer treatment incl. understanding of mechanisms; and long-term effects on cancer risk of low doses from CT in children. Third, it will develop science-based consensus policy recommendations for the effective protection of patients, workers and the general public.
Within the 4-year project a multi-disciplinary consortium will, in close interaction with European medical associations, MELODI and EURADOS (1), develop a tool to determine image quality to maximise optimisation of RP in medical imaging, (2) improve and develop new individual organ/anatomical structure dosimetry from chest CT, I131 administration, fluoroscopy-guided procedures, hybrid imaging, and RT for breast cancer and interlinks with image quality measures, (3) conduct epidemiological studies of consequences of RT and CT, (4) identify potential novel imaging and circulating biomarkers and mechanisms of radiation effects, (5) develop innovative risk models, (6) develop and implement for the first time a European repository of patient dose and imaging data, (7) develop science-based recommendations, and (8) introduce novel approaches to bring together the nuclear and medical sectors.

Programme(s)

H2020-Euratom-1.4. - Foster radiation protection

Topic(s)

NFRP-9 - Impacts of low dose radiation exposure

Call for proposal

NFRP-2016-2017-1

See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG

Address

Neutorgasse 9/2
1010 Vienna

Austria

Activity type

Research Organisations

EU Contribution

€ 503 750

Website

Contact the organisation

Participants (34)

Sort alphabetically

Sort by EU Contribution

Expand all

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA

Spain

EU Contribution

€ 727 983,25

UNIVERSITE PARIS DESCARTES

France

EU Contribution

€ 260 876,25

PANEPISTIMIO KRITIS

Greece

EU Contribution

€ 364 000

THE ROYAL MARSDEN NATIONAL HEALTH SERVICE TRUST

United Kingdom

EU Contribution

€ 678 902,50

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 871 447,75

INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE

France

EU Contribution

€ 854 591,25

OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG

Germany

EU Contribution

€ 329 728,75

INSTITUTO POLITECNICO DE COIMBRA

Portugal

EU Contribution

€ 188 800

VASTRA GOTALANDS LANS LANDSTING

Sweden

EU Contribution

€ 130 000

UNIVERSITAT POLITECNICA DE CATALUNYA

Spain

EU Contribution

€ 62 500

INSTYTUT MEDYCYNY PRACY IMIENIA PROF. DRA MED. JERZEGO NOFERA W LODZI

Poland

EU Contribution

€ 22 500

B-COM

France

EU Contribution

€ 196 608,75

UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ

Germany

EU Contribution

€ 194 952,50

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 338 000

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 429 856,25

STUDIECENTRUM VOOR KERNENERGIE / CENTRE D'ETUDE DE L'ENERGIE NUCLEAIRE

Belgium

EU Contribution

€ 383 176,25

UNIVERSITEIT GENT

Belgium

EU Contribution

€ 337 550

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

EU Contribution

€ 224 786,25

PHILIPPS UNIVERSITAET MARBURG

Germany

EU Contribution

€ 117 015

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 504 322,50

Associação para Investigação e Desenvolvimento da Faculdade de Medicina

Portugal

EU Contribution

€ 444 517,85

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

Germany

EU Contribution

€ 57 656,25

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

Italy

EU Contribution

€ 250 432,15

UNIVERSITY OF BRISTOL

United Kingdom

EU Contribution

€ 4 934,59

STICHTING VUMC

Netherlands

EU Contribution

€ 160 625

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 199 615

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

EU Contribution

€ 263 971,69

UNIVERSITAT AUTONOMA DE BARCELONA

Spain

EU Contribution

€ 279 875

ISTITUTO SUPERIORE DI SANITA

Italy

EU Contribution

€ 50 625

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 46 848,75

INSTITUT CLAUDIUS REGAUD

France

EU Contribution

€ 50 812,50

INSTITUT CATALA D'ONCOLOGIA

Spain

EU Contribution

€ 108 402,50

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 226 605,41

MEDIZINISCHE HOCHSCHULE BRANDENBURG CAMPUS GMBH

Germany

EU Contribution

€ 128 876,81

Project information

MEDIRAD

Grant agreement ID: 755523

Project website

Status

Ongoing project

Start date

1 June 2017
End date

28 February 2022

Funded under:

H2020-Euratom-1.4.

Overall budget:

€ 9 995 145,75
EU contribution

€ 9 995 145,75

Coordinated by:

EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG

Austria

Periodic Reporting for period 1 - MEDIRAD (Implications of Medical Low Dose Radiation Exposure)

Reporting period: 2017-06-01 to 2018-11-30

Summary of the context and overall objectives of the project

MEDIRAD aims to enhance the scientific bases and clinical practice of radiation protection (RP) in the medical field and addresses the need to better understand and evaluate the health effects of low-dose ionising radiation (IR) exposure from diagnostic and therapeutic imaging and from off-target effects in radiotherapy (RT).
MEDIRAD pursues 3 major operational objectives:
• To improve organ dose estimation and registration to inform clinical practice, optimise doses, set recommendations and provide adequate dosimetry for clinical-epidemiological studies of effects resulting from exposures to IR in medicine;
• To evaluate and understand the effects of medical exposures, focusing on two major endpoints of public health relevance: cardiovascular effects of low to moderate doses of radiation from RT in breast cancer treatment including understanding of mechanisms, and long-term carcinogenic effects of low doses from CT in children;
• To develop science-based consensus recommendations for the effective protection of patients, workers and the general public.
To fulfil these, the 4-year MEDIRAD project relies on a multi-disciplinary consortium involving 33 partners from 14 European countries, a Scientific Advisory Board (with world-renowned experts in the fields of imaging, radiobiology, dosimetry, medical physics, epidemiology and ethics), a Stakeholder Board (with representatives from the medical associations EANM, EFOMP, EFRS, ESR and ESTRO, as well as the EURADOS, EURAMED and MELODI platforms on RP research, and the EPF), and a Stakeholder Forum (including health professionals, patients, nuclear scientists, policy-makers, competent authorities and representatives from international organisations).

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Logo of MEDIRAD

Project information

MEDIRAD

Grant agreement ID: 755523

Project website

Status

Ongoing project

Start date

1 June 2017
End date

28 February 2022

Funded under:

H2020-Euratom-1.4.

Overall budget:

€ 9 995 145,75
EU contribution

€ 9 995 145,75

Coordinated by:

EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG

Project information

MEDIRAD

Grant agreement ID: 755523

Project website

Status

Ongoing project

Start date

1 June 2017
End date

28 February 2022

Funded under:

H2020-Euratom-1.4.

Overall budget:

€ 9 995 145,75
EU contribution

€ 9 995 145,75

Coordinated by:

EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG

Download

PDF

XML

Last update: 14 October 2019

Record number: 211042

CORDIS

Objective

Coordinator

Participants (34)

Project information

Periodic Reporting for period 1 - MEDIRAD (Implications of Medical Low Dose Radiation Exposure)

Project information

Deliverables

Publications

Project information

Project information

Download

Please tell us what you think of CORDIS

CORDIS

Objective

Coordinator

Participants (34)

Project information

Periodic Reporting for period 1 - MEDIRAD (Implications of Medical Low Dose Radiation Exposure)

Project information

Deliverables

Publications

Project information

Project information

Share this page

Download